Abstract
INTRODUCTION
Identifying low-cost, minimally-invasive screening instruments for Alzheimer’s disease (AD) trial enrichment will improve the efficiency of AD trials.
METHODS
A total of 685 cognitively normal (CN) individuals and individuals with mild cognitive impairment (MCI) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were grouped according to cutoffs of genetic risk factor (G) polygenic hazard score (PHS) and tau pathology (T) plasma phosphorylated tau-181 (p-tau181) into four groups: G+T+, G-T-, G+T-, and G-T+. We assessed the associations between group level and longitudinal cognitive decline and AD conversion. Power analyses compared the estimated sample size required to detect differences in cognitive decline.
RESULTS
The G+T+ group was associated with faster cognitive decline and higher AD risk. Clinical trials enrolling G+T+ participants would benefit from significantly reduced sample sizes compared with similar trials using only single makers as an inclusion criterion.
DISCUSSION
The combination of two low-cost, minimally-invasive measures—genetics and plasma biomarkers—would be a promising screening procedure for clinical trial enrollment.
Highlights
Participants with unimpaired or mildly impaired cognition were grouped based on cutoffs on genetic risk factors (G: polygenic hazardous score [PHS]) and Alzheimer’s pathology (T: baseline plasma phosphorylated tau-181 [p-tau181]).
Participants with high PHSs and plasma p-tau181 levels (G+T+) were at risk of faster cognitive decline and AD progression.
The combination of PHS and plasma p-tau181 could enhance clinical trial enrichment more effectively than using single biomarkers.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Xin Wang,
Xinran Wang,
Steven D. Edland,
Iris J. Broce,
Anders M. Dale,
Sarah J. Banks,
for the Alzheimer’s Disease Neuroimaging Initiative | October 23, 2024